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The carbonic anhydrases (CAs) comprise a family of evolutionarily ancient enzymes found ubiquitously in nature. They have
important roles in facilitating transport of carbon dioxide and protons in the intracellular space, across biological membranes and in
the unstirred layers of the extracellular space. The tumour-associated isoenzymes, CAIX and CAXII, are expressed in a wide variety
of malignancies and appear to be tightly regulated by microenvironmental hypoxia. CAIX expression is linked to poor prognosis in a
number of human tumours, and may be a marker of aggressive malignant phenotype and a mechanism of progression. Inhibitors of
CA may inhibit tumour growth and invasion, with consequent therapeutic potential.
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The carbonic anhydrase (CA) family of zinc metalloenzymes is
phylogenetically ancient, diverse in structure and its members are
found in almost every living organism (Tripp et al, 2001). This
short review aims to address recent advances in the association of
CA with cancer biology, with particular attention to the novel
tumour-associated CAs, IX and XII.
FUNCTIONS OF CA
H2O þ CO2 , Hþ þ HCO 
3 ð1Þ
The above reaction (1) is ubiquitous in nature, involving the
interchange of gaseous and ionic species crucial to a wide range of
physiological and biochemical processes. Biological membranes
form an effective barrier to the passive diffusion of bicarbonate
and hydrogen ion, whereas carbon dioxide is highly membrane
permeable, and it has been suggested that CA initially evolved to
facilitate trans-cellular carbon dioxide transport rather than its
more familiar role in respiratory gas exchange (Henry and
Swenson, 2000). Certainly, at the single-cell level, carbon dioxide
diffuses more rapidly in buffer solutions and across artificial
membranes than would be expected from its diffusion coefficients,
and this facilitated diffusion is abolished by the inhibition of CA
activity (Geers and Gros, 2000).
Carbonic anhydrase may also confer directionality on carbon
dioxide transport across membranes, maintaining high levels of
the gas in solution on the upstream side of the membrane, and
causing acidification of the downstream boundary layer thus
maintaining the concentration gradient to drive diffusion (Figure 1A).
In addition to facilitating passive diffusion, CAs may act in
concert with membrane-associated ion transport systems such as
the sodium–hydrogen exchanger (NHE) and chloride–bicarbo-
nate anion exchanger (AE). Indeed, CAII is known to bind to the
cytoplasmic tail of the band III AE in the erythrocyte, forming a
metabolon, a physically associated complex of proteins in a
sequential metabolic pathway (Sterling et al, 2001) (Figure 1B).
The three distinct CA families (a, b and g)s h o wn os i g n i f i c a n t
sequence identity and appear to have completely separate
phylogenetic origins, a remarkable example of convergent evolution.
THE a-CA FAMILY
There are 14 known members of this family, the only CAs to be
found in mammalian cells. Eleven members express CA activity,
whereas the three CA-related-polypeptides (CA-RPs VIII, XI and
XIII) lack one or more of the critical histidine residues responsible
for zinc ion binding at the active site. CAII is thought to be the
most active enzyme found in nature, with a Kcat of around 10
6s
 1,
providing near-instantaneous equilibrium between the chemical
species.
The family may be subdivided, on the basis of cellular
localization, into cytosolic (CAs I, II, III, VII), membrane
associated (CAs IV, IX, XII, XIV), mitochondrial (CAV) and
secreted (CAVI). On the basis of intron:exon relations, the
cytoplasmic and mitochondrial groups seem distinct from the
trans-membrane and secreted enzymes. The highly heterogeneous
distribution of the various isoenzymes within tissues, organs and
cells suggests functionally distinct roles in processes as diverse as
acid–base balance, gas exchange, ion transport, carbon fixation
and mucosal protection.
Table 1 describes the expression patterns of the cytoplasmic CAs
in human tumours. It would appear that CAs I and II have some
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www.bjcancer.comtured with breast cancer cells, contained a CA domain very similar
to that of CAIV (Pastorek et al, 1994). This 54/58kDa N-
glycosylated transmembrane protein also has an N-terminal region
which shows significant homology to the keratan sulphate-binding
domain of aggrecan (Opavsky et al, 1996), the major proteoglycan
of articular cartilage, thought to be important in maintenance of
tissue hydration. This pattern of a CA-related domain being found
adjacent to a proteoglycan domain is also found in a number of
other proteins, most notably the receptor protein tyrosine
phosphatases (RPTPs b and g) and the rat neural protein,
phosphacan. The CA-like domain of RPTPb is known to act as a
ligand-binding site for the neuronal cell recognition molecule
contactin (Peles et al, 1995), suggesting a role distinct from
catalysis for this domain.
The MN gene thus appears to be chimeric in nature, arising
from exon shuffling. Its sequence has been published (Opavsky
et al, 1996), the original cDNA sequence corrected (Pastorek et al,
1994) and the sequences from tumours and normal tissue shown to
be identical (Pastorekova et al, 1997). In 1996, the gene was
renamed CA9 and its product has shown significant CA activity
when expressed in COS cells (Sly, 2000), a truncated construct even
showing equivalent activity to CAII (Wingo et al, 2001). Targeted
disruption of CA9 gene expression in a murine model results in
gastric glandular hyperplasia with proliferation of mucus-secreting
pit cells, but otherwise normal development (Gut et al, 2002).
CA9 has been suggested to be a proto-oncogene on the basis of a
number of observations:
(1) Expression in HeLa cells is density dependent, CAIX expres-
sion increasing in confluent cultures (Zavada et al, 1993)
(2) In HeLa/fibroblast hybrid cell lines, tumorigenicity in nude
mice correlated with CA expression levels (Pastorek et al,
1994)
(3) Transfection of NIH3T3 fibroblasts with the CA9 gene resulted
in a transient transformation, with uncontrolled proliferation,
growth in soft agar and morphological changes. After a few
passages, the cells reverted to normal phenotype (Pastorek
et al, 1994)
(4) There is differential expression of CAIX between normal tissue
and tumour specimens. Immunostaining and Northern blot
techniques have revealed an extremely limited distribution
in normal tissues, moderate expression being found in
gastric mucosa, fetal lung and muscle. More sparse expression
is found in small intestine, biliary tree and the male
reproductive tract. Conversely, CAIX mRNA has been found
in 50 of 87 malignant cell lines in one study (Ivanov et al,
2001)
The association with gastric hyperplasia in the mouse knockout
suggests that any action may be tissue specific.
Table 1 Expression of cytoplasmic CAs in human tumours
Tumour CA expression pattern
Central Nervous System CAII staining maintained in astrocytomas, oligodendrocytomas and medulloblastomas. Staining appeared stronger in more malignant tumours
(Parkkila et al, 1995)
Colorectal CAsI and II expression reduced as differentiation lost, with reduced immunostaining correlating with malignant progression. CAI expression
associated with reduced vascular invasion and good prognosis in colorectal tumours, CAII expression associated with good prognosis in rectal
tumours (Bekku et al, 2000).
Lung CAI and II expression reduced in squamous cell and adenocarcinoma (Chiang et al, 2002).
Haematological CAI is a potential marker of erythroid differentiation in blast cells (Walloch et al, 1986) and CAII is found in a majority of acute leukaemias
(Leppilampi et al, 2002).
Bekku S, Mochizuki H, Yamamoto T, Ueno H, Takayama E, Tadakuma T (2000) Expression of carbonic anhydrase I or II and correlation to clinical aspects of colorectal cancer.
Hepatogastroenterology 47: 998–1001
Chiang WL, Chu SC, Yang SS, Li MC, Lai JC, Yang SF, Chiou HL, Hsieh YS (2002) The aberrant expression of cytosolic carbonic anhydrase and its clinical significance in human
non-small cell lung cancer. Cancer Lett 188: 199–205
Leppilampi M, Koistinen P, Savolainen ER, Hannuksela J, Parkkila AK, Niemela O, Pastorekova S, Pastorek J, Waheed A, Sly WS, Parkkila S, Rajaniemi H (2002) The expression of
carbonic anhydrase II in hematological malignancies. Clin Cancer Res 8: 2240–2245
Parkkila S, Parkkila AK, Juvonen T, Lehto VP, Rajaniemi H (1995) Immunohistochemical demonstration of the carbonic anhydrase isoenzymes I and II in pancreatic tumours.
Histochem J 27: 133–138
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Figure 1 (A) Hydrogen ion produced by anaerobic metabolism within
the cell must first be converted to carbon dioxide to facilitate diffusion
across the lipid bilayer. This reaction with bicarbonate is catalysed by
cytoplasmic CA. Once carbon dioxide has diffused into the extracellular
space, CA activity in the boundary layer may regenerate protons,
maintaining the carbon dioxide diffusion gradient. (B) The NHE is one
method by which protons may be actively pumped from the cell.
Alternatively, bicarbonate in the extracellular space (regenerated from
carbon dioxide hydration with CA catalysis) may be imported into the cell
via the chloride–bicarbonate AE. This bicarbonate may recombine with a
proton in the cytoplasm to undertake further shuttling across the
membrane. This recycling of bicarbonate with net proton extrusion is
known as a Jacobs–Stewart cycle. The AE has recently been shown to bind
CAII on its intracellular surface
Diagnostic, prognostic and therapeutic implication
CPS Potter and AL Harris
3
British Journal of Cancer (2003) 89(1), 2–7 & 2003 Cancer Research UKCAXII
Originally patented in 1994 as a novel protein specific for lung
cancer cells, CAXII is now recognised to be present in a wide
variety of normal tissues and tumours (Tureci et al, 1998). The
39kDa transmembrane protein shows a great deal of structural
homology with CAIX, but lacks the proteoglycan domain. X-ray
crystallography has revealed a dimeric structure, with a character-
istic active site which may be susceptible to specific inhibitors
(Whittington et al, 2001). Its expression in tissues with high
absorptive capacities for water (colon, collecting duct, ascending
loop of Henl) suggests a role in normal tissue physiology distinct
to that of CAIX (Parkkila et al, 2000a).
CONTROL OF CAIX AND CAXII EXPRESSION
A number of microenvironmental factors were initially shown to
induce CAIX expression in vitro – notably confluent growth and
suspension culture (Lieskovska et al, 1999).
Both CAs were shown by our group to be induced by hypoxia in
a wide range of malignant cells in vitro including bladder, breast,
cervical and lung cancer lines (Wykoff et al, 2000). The von-
Hippel–Lindau tumour suppressor gene appears to play a critical
role in this process, clear cell renal carcinoma cell lines with
mutant VHL expressing both CAIX and CAXII constitutively. Both
RNA differential display (Ivanov et al, 1998) and RNAse protection
assay (Wykoff et al, 2000) have shown that reintroduction of the
wild-type VHL gene into the same cell lines results in down-
regulation of these CAs in normoxia, with a restoration of the
hypoxic response. We found a binding site for hypoxia inducible
factor 1a (HIF-1a), the hypoxia response element (HRE) in the
CA9 promoter and demonstrated that hypoxic induction is absent
in cell lines defective for the HIF pathway, but may be restored by
transfection of human HIF-1a. Mutations made within the core of
the HRE also abrogate the hypoxic response, confirming the
pivotal role of the HIF pathway (Wykoff et al, 2000). The strong
inducibility in hypoxia that is conferred by the minimal CA9
promoter may be of use in targeting gene therapy vectors to areas
of tumour hypoxia (Dachs et al, 1997). Other factors may be of
significance in producing the strong upregulation of CAIX in
cancer, since p53 mutation modulates expression, the promoter is
less methylated in cancer (Cho et al, 2001) and contains binding
sites for activator protein 1 and specificity protein transcription
factors 1 and 3 (Kaluzova et al, 2001).
Other HIF target genes include glucose transporters, glycolytic
enzymes and angiogenic growth factors such as VEGF, all essential
for survival in a hostile, hypoxic environment. The tumour-
associated CAs may play a role in maintenance of an acidic
extracellular pH, an important element of the malignant phenotype
(Ivanov et al, 2001). Although lactate produced by glycolysis under
hypoxic conditions is a significant contributor to acidic extra-
cellular pH, there is also a substantial contribution from carbonic
acid (Griffiths et al, 2001).
CAIX AS A MARKER OF HYPOXIA
Hypoxic tumours are known to have a relatively poor prognosis,
independent of the modality of treatment used (Vaupel, 1997).
Current methods of measuring tumour oxygenation are either
invasive (Eppendorf microelectrode) or require administration of
chemical agents (e.g. pimonidazole). There are obvious benefits of
an endogenous hypoxia biomarker that is nondiffusible (unlike
VEGF) and easily processed in paraffin sections for staining. Thus,
it is important to demonstrate that the in vitro findings with regard
to CA induction by hypoxia can be confirmed in vivo.
In a multicellular spheroid model, CAIX immunostaining was
more marked on the plasma membrane of cells from the innermost
layers, with a distribution similar to that of pimonidazole.
Similarly, human glioma xenografts grown in immunodeficient
mice show more CAIX-staining in poorly perfused and hypoxic
areas. The CAIX-stained cells remained viable when plated out,
and were shown to be more radioresistant than unstained cells
(Olive et al, 2001).
In vivo studies in human tumours have confirmed these
findings, revealing a predominantly perinecrotic staining pattern.
In squamous cancers of the head and neck, we observed a gradient
of CA9 expression with highest levels adjacent to frank necrosis
and considerable overlap with pimonidazole staining (Beasley et al,
2001). Biopsies of invasive cervical carcinomas also showed a good
correlation between staining for the two hypoxia markers, CA9
staining being more extensive in almost all cases (Olive et al, 2001).
CD34 staining of the microvasculature reveals a median distance
of 80mm between a vessel and CAIX expression in squamous head
and neck tumours, which corresponds to a tissue oxygen tension
of around 1%. This corresponds to the level at which HIF-1a and
its target genes are induced. In this study, CAIX staining was also
significantly related to levels of tumour necrosis (Beasley et al,
2001).
Papillary renal tumours, breast, bladder and ovarian cancers
show a similar perinecrotic CAIX distribution. Conversely, renal
clear cell carcinomas showed a uniform staining pattern irrespec-
tive of areas of hypoxia and necrosis, suggesting a constitutively
upregulated HIF pathway in these tumours (Wykoff et al, 2000).
Definitive measurement of tumour hypoxia by Eppendorf
microelectrode has confirmed that there is a significant positive
correlation between the hypoxic fraction of advanced cervical
carcinomas and the extent of CAIX immunostaining (Loncaster
et al, 2001). Whether the above findings will translate to significant
prognostic information in a prospective trial remains to be
determined, but accumulating evidence from a number of clinical
studies (see Table 2) suggests that this may indeed be the case.
CARBONIC ANHYDRASE AS A TARGET FOR
THERAPY
Further evidence of the importance of the CAs in the oncogenic
process comes from the use of CA inhibitors, most notably the
heterocyclic and aromatic sulphonamides of which acetazolamide
is the most prominent.
In bicarbonate-free medium, sulphonamides were effective in
reducing growth rates of lymphoma cell lines according to their
order of potency in CA inhibition (Chegwidden et al, 2000). The
growth inhibition was reversed by supplementing the medium with
nucleotide precursors, suggesting that these may be depleted most
readily by the high metabolic flux of the transformed cell in a low
bicarbonate environment. The critical step may involve carbamoyl
synthetase II, a cytosolic enzyme that utilises bicarbonate for the
first step in pyrimidine nucleotide biosynthesis.
Many novel sulphonamide derivatives have been shown to have
growth-inhibitory effects on a variety of malignant cell lines in
vitro, often at concentrations in the nanomolar range (Supuran
et al, 2001). However, some sulphonamides without any CA-
inhibitory activity also show growth-inhibitory effects, possibly
because of inhibition of tubulin polymerisation. There is also
potentially a degree of crossover with inhibition of other zinc
metalloenzymes, notably the matrix metalloproteinases.
Acetazolamide has been shown to reduce invasiveness of four
RCC cell lines in vitro by 18–74%, although the only cell line
shown to express CAIX was also the least affected (Parkkila et al,
2000b). The concentrations used were orders of magnitude greater
than that needed to inhibit CA.
Invasiveness is known to increase in cells cultured in low pH
medium, and it is possible that the presence of CA activity may
promote this acidification of the extracellular space, with
Diagnostic, prognostic and therapeutic implication
CPS Potter and AL Harris
4
British Journal of Cancer (2003) 89(1), 2–7 & 2003 Cancer Research UKconcomitant activation of enzymes required for matrix degrada-
tion (Martinez-Zaguilan et al, 1996).
Acetazolamide has shown antitumour properties in a murine
fibrosarcoma model, producing significant growth delays when
used as a single agent, and additive growth delays in combination
with a number of chemotherapeutic agents (Teicher et al, 1993).
In the clinical setting, the differential expression of CAIX in
renal cancers has provided a target for radioimmunotherapy,
antibody-mediated gene transfer and vaccination strategies (Tso
et al, 2001), and phase I/II trial results with iodine-131 labelled
murine monoclonal antibodies have been performed with some
antitumour activity (Divgi et al, 1998). The development of a
Table 2 Expression of membrane-associated CAs in human tumours
Tumour CA expression pattern
Renal CAIX expressed in renal cell carcinomas and Von Hippel–Lindau-associated tumours (Wykoff et al, 2000), but not normal tissue or other renal
cancers. CAIX is identical to G250 tumour-associated antigen, therapeutic target in clinical trials (Divgi et al, 1998). PCR of peripheral blood may
detect CAIX-positive renal cancer cells in circulation, potential diagnostic biomarker (de la Taille et al, 2000). CAXII expression found in most
oncocytomas and renal cell carcinomas (Parkkila et al, 2000)
Cervical CAIX expressed in majority cervical squamous cell carcinomas, significant independent negative predictor of survival (Loncaster et al, 2001).
Expression in smear parallels that of tissue biopsies and correlates with clinically significant disease at biopsy (Liao and Stanbridge, 2000).
Squanous carcinoma of
the head and neck
CAIX Immunostaining perinecrotic and associated with advanced disease (Beasley et al, 2001), poor radiosensitivity and short survival
(Koukourakis et al, 2001).
Lung Fifty percent squamous carcinoma and 16% adenocarcinomas express CAIX (O’Byrne et al, 2001), absent in dysplastic (Vermylen et al, 1999)
and normal tissues.Expression increases with advanced stage disease and is a significant adverse prognostic factor (Giatromanolaki et al, 2001).
Breast Fifty percent ductal carcinoma-in situ and 29% invasive carcinomas positive for CAIX immunostaining, associated with necrosis, high-grade and
poor prognosis. (Chia et al, 2001) CAXII staining found in 89% normal breast samples, 84% DCIS and 71% invasive carcinomas, associated with
low-grade and good prognosis. (Wykoff et al, 2001)
Colorectal CAIX exspression parallels cellular proliferation and increases with reduced cellular differentiation being more pronounced in frank
adenocarcinoma than dysplasia or adenomatous disease (Saarnio et al, 1998). CAXII expression is also increased in adenocarcinoma (Kivela et al,
2000a)
Oesophageal CAIX expression reduced in adenocarcinoma compared to dysplasia (Turner et al, 1997)
Gastric CAIX expression reduced in gastric carcinoma (Pastorekova et al, 1997)
Biliary tree CAIX expression increased in hyperplastic, dysplastic (Kivela et al, 2000b) and malignant ductal epithelium (Saarnio et al, 2001).
Bladder CAIX expression increased in superficial tumours (Turner et al, 2002)
Beasley NJ, Wykoff CC, Watson PH, Leek R, Turley H, Gatter K, Pastorek J, Cox GJ, Ratcliffe P, Harris AL (2001) Carbonic anhydrase IX, an endogenous hypoxia marker,
expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density. Cancer Res 61: 5262–5267
Chia SK, Wykoff CC, Watson PH, Han C, Leek RD, Pastorek J, Gatter KC, Ratcliffe P, Harris AL (2001) Prognostic significance of a novel hypoxia-regulated marker, carbonic
anhydrase ix, in invasive breast carcinoma. J Clin Oncol 19: 3660–3668
de la Taille A, Buttyan R, Katz AE, McKiernan J, Burchardt M, Burchardt T, Chopin DK, Sawczuk IS (2000) Biomarkers of renal cell carcinoma. Past and future considerations. Urol
Oncol 5: 139–148
Divgi CR, Bander NH, Scott AM, O’Donoghue JA, Sgouros G, Welt S, Finn RD, Morrissey F, Capitelli P, Williams JM, Deland D, Nakhre A, Oosterwijk E, Gulec S, Graham MC,
Larson SM, Old LJ (1998) Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma. Clin Cancer Res 4: 2729–
2739
Giatromanolaki A, Koukourakis MI, Sivridis E, Pastorek J, Wykoff CC, Gatter KC, Harris AL (2001) Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic
pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res 61: 7992–7998
Kivela A, Parkkila S, Saarnio J, Karttunen TJ, Kivela J, Parkkila AK, Waheed A, Sly WS, Grubb JH, Shah G, Tureci O, Rajaniemi H (2000a) Expression of a novel transmembrane
carbonic anhydrase isozyme XII in normal human gut and colorectal tumors. Am J Pathol 156: 577–584
Kivela AJ, Parkkila S, Saarnio J, Karttunen TJ, Kivela J, Parkkila AK, Pastorekova S, Pastorek J, Waheed A, Sly WS, Rajaniemi H (2000b) Expression of transmembrane carbonic
anhydrase isoenzymes IX and XII in normal human pancreas and pancreatic tumours. Histochem Cell Biol 114: 197–204
Koukourakis MI, Giatromanolaki A, Sivridis E, Simopoulos K, Pastorek J, Wykoff CC, Gatter KC, Harris AL (2001) Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor
vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy. Clin Cancer Res 7: 3399–3403
Liao SY, Stanbridge EJ (2000) Expression of MN/CA9 protein in Papanicolaou smears containing atypical glandular cells of undetermined significance is a diagnostic biomarker of
cervical dysplasia and neoplasia. Cancer 88: 1108–1121
Loncaster JA, Harris AL, Davidson SE, Logue JP, Hunter RD, Wycoff CC, Pastorek J, Ratcliffe PJ, Stratford IJ, West CM (2001) Carbonic anhydrase (CA IX) expression, a potential
new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res 61: 6394–6399
O’Byrne KJ, Cox G, Swinson D, Richardson D, Edwards JG, Lolljee J, Andi A, Koukourakis MI, Giatromanolaki A, Gatter K, Harris AL, Waller D, Jones JL (2001) Towards a
biological staging model for operable non-small cell lung cancer. Lung Cancer 34: S83–S89
Parkkila S, Parkkila AK, Saarnio J, Kivela J, Karttunen TJ, Kaunisto K, Waheed A, Sly WS, Tureci O, Virtanen I, Rajaniemi H (2000) Expression of the membrane-associated carbonic
anhydrase isozyme XII in the human kidney and renal tumors. J Histochem Cytochem 48: 1601–1608
Pastorekova S, Parkkila S, Parkkila AK, Opavsky R, Zelnik V, Saarnio J, Pastorek J (1997) Carbonic anhydrase IX, MN/CA IX: analysis of stomach complementary DNA sequence
and expression in human and rat alimentary tracts. Gastroenterology 112: 398–408
Saarnio J, Parkkila S, Parkkila AK, Haukipuro K, Pastorekova S, Pastorek J, Kairaluoma MI, Karttunen TJ (1998) Immunohistochemical study of colorectal tumors for expression of a
novel transmembrane carbonic anhydrase, MN/CA IX, with potential value as a marker of cell proliferation. Am J Pathol 153: 279–285
Saarnio J, Parkkila S, Parkkila AK, Pastorekova S, Haukipuro K, Pastorek J, Juvonen T, Karttunen TJ (2001) Transmembrane carbonic anhydrase, MN/CA IX, is a potential biomarker
for biliary tumours. J Hepatol 35: 643–649
Turner JR, Odze RD, Crum CP, Resnick MB (1997) MN antigen expression in normal, preneoplastic, and neoplastic esophagus: a clinicopathological study of a new cancer-
associated biomarker. Hum Pathol 28: 740–744
Turner KJ, Crew JP, Wykoff CC, Watson PH, Poulsom R, Pastorek J, Ratcliffe PJ, Cranston D, Harris AL (2002) The hypoxia-inducible genes VEGF and CA9 are differentially
regulated in superficial vs invasive bladder cancer. Br J Cancer 86: 1276–1282
Vermylen P, Roufosse C, Burny A, Verhest A, Bosschaerts T, Pastorekova S, Ninane V, Sculier JP (1999) Carbonic anhydrase IX antigen differentiates between preneoplastic
malignant lesions in non-small cell lung carcinoma. Eur Respir J 14: 806–811
Wykoff CC, Beasley N, Watson PH, Campo L, Chia SK, English,R, Pastorek J, Sly WS, Ratcliffe P, Harris AL (2001) Expression of the hypoxia-inducible and tumor-associated
carbonic anhydrases in ductal carcinoma in situ of the breast. Am J Pathol 158: 1011–1019
Wykoff CC, Beasley NJ, Watson PH, Turner KJ, Pastorek J, Sibtain A, Wilson GD, Turley H, Talks KL, Maxwell PH, Pugh CW, Ratcliffe PJ, Harris AL (2000) Hypoxia-inducible
expression of tumor-associated carbonic anhydrases. Cancer Res 60: 7075–7083
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cycles of treatment.
Many chemotherapeutic drugs are weak acids or bases, their
pKa’s being in the physiological range. As most of these
drugs enter the cell by passive diffusion and the plasma membrane
is relatively impermeable to ionised species, slight differences in
pH on either side of the membrane may result in dramatic
alterations in the distribution of the drug due to ion trapping.
In areas of tumour distant from the vasculature, extracellular
pH may be expected to drop, whereas the intracellular pH
remains relatively constant, increasing the intra- to extracellular
pH gradient and favouring the uptake of weak acid drugs.
Many clinically useful chemotherapeutic drugs are weak bases
(e.g. doxorubicin, bleomycin, mitoxantrone), whose uptake
in animal models may be enhanced by bicarbonate admini-
stration, reducing the extracellular acidity of tumours
(Raghunand and Gillies, 2001). Whether CA inhibitors may
be effective in reducing this tumour acidity and consequently
have a role in combination chemotherapy remains to be
demonstrated.
CONCLUSIONS
The intracellular pH in solid tumours remains close to the
physiological value despite the relative acidity of the interstitial
space under these circumstances, suggesting that malignant cells
extrude protons more avidly than their untransformed counter-
parts. Studies on retinal pigmented epithelia have demonstrated a
drop in intracellular pH following selective inhibition of extra-
cellular CA by a membrane-impermeant agent, associated with
reduced activity of the NHE (Wu et al, 1998). Similar effects have
been seen in muscle, with reduced proton and lactate export when
extracellular CA is inhibited (Geers and Gros, 2000). Acetazola-
mide will also inhibit activity of the AE,1 a protein functionally and
physically linked to CAII and critical to maintaining cytoplasmic
pH (Sterling et al, 2001). Both NHE and AE expression is also
modulated by the HIF pathway (Karumanchi et al, 2001).
Extracellular CA would appear to be in an ideal position to
convert carbon dioxide diffused across the plasma membrane to
protons and bicarbonate, the latter being transported back into the
cell by the AE, forming a Jacobs–Stewart cycle (Figure 1B), with
net extrusion of protons.
The consequent acidification of the extracellular space would in
addition be permissive for invasion, and have an adverse effect on
cell-mediated immunity. Hypoxia-induced apoptosis may also be
dependent on a drop in extracellular pH (Schmaltz et al, 1998)
providing selective pressure for apoptosis-resistant malignant
clones. The acidic microenvironment of tumours has long been
assumed to be because of excess lactate production by anaerobic
metabolism, but cells deficient in lactate production produce
equally acidic interstiae (Griffiths et al, 2001) suggesting the
importance of a distinct pathway for acidification such as that
outlined above.
In addition to its role in transmembrane solute transport,
extracellular CA may be important in facilitated diffusion of
protons/carbon dioxide in the unstirred layers of the extracellular
space. Rapid interconversion of the two species in the presence of
mobile buffers will result in more rapid diffusion down the
concentration gradient to better perfused areas, dissipating pH
gradients that may otherwise preclude further tumour growth
(Griffiths et al, 2001).
The presence of a proteoglycan/cell adhesion domain on the
CAIX protein is highly suggestive of a role in cell–cell or cell–
matrix interaction. The majority of CAIX expression in normal
tissues would appear to be on the basolateral plasma membrane,
and cell attachment to CAIX in vitro can be inhibited by
monoclonal antibodies directed to this domain (Zavada et al,
2000). The cytoplasmic tail has not yet been shown to partake in a
signal transduction pathway (unlike the RPTPs), but this has not
been fully investigated.
As more is learnt about the mechanism of action of the tumour-
associated CAs, it is hoped that they may make the transition
from biomarkers of hypoxia and differentiation to essential
tumour enzymes and therapeutic targets. The development of
specific inhibitors for CAs IX and XII may facilitate this pro-
cess, leading to a greater understanding of the role in tumour
biology of these recently discovered yet phylogenetically ancient
enzymes.
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